PRIMA Trial

Data from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a new standard of care for patients with folate receptor α–positive, platinum-resistant ovarian cancer, says Kathleen N. Moore, MD, MS.

Dr. Dmitriy Zamarin speaks with Cancer Network about the findings of a phase II trial in platinum-resistant ovarian cancer patients.

Preliminary overall survival data with atezolizumab plus bevacizumab and chemotherapy in recurrent ovarian cancer in the phase 3 ATALANTE trial appear to warrant further analysis.

Dr. Ranjit Manchanda speaks with Cancer Network about using population testing to predict and prevent gynecologic cancers.

Mirvetuximab soravtansine-gynx may have the potential to become a new standard for patients with folate receptor α–positive, platinum-resistant ovarian cancer, experts say.

Data from the phase 3 MIRASOL trial support the European marketing authorization application for mirvetuximab soravtansine as a treatment for folate receptor α–positive, platinum-resistant ovarian cancer.